Brief: Geneuro’S ANGEL-MS Phase 2b Extension Study Confirms Neuroprotective Effects Of Temelimab In MS

Geneuro SA

12/03/2019 09:12

March 12 (Reuters) - GENEURO SA  GNRO.PA :
    * GENEURO’S ANGEL-MS PHASE 2B EXTENSION STUDY CONFIRMS AND
EXTENDS
THE NEUROPROTECTIVE EFFECTS OF TEMELIMAB IN MS
    * LONG-TERM NEUROPROTECTIVE EFFECTS CONFIRMED IN PATIENTS
TREATED
UP TO TWO YEARS
    * EXCELLENT TOLERABILITY CONTINUED TO BE OBSERVED, WITH NO
DOSE-LIMITING SAFETY SIGNALS

Source text for Eikon:  ID:nBw6GC7BXa 
Further company coverage:  GNRO.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com;))